Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12594000 | 0.88 | TUBB1 (0.42) | HDAC1HDAC6CYP2A6ALDH1A1SMN1; SMN2 | |
| SCHEMBL22490227 | 0.84 | ALDH1A3 (0.37) | HDAC1HDAC6CYP2A6ALDH1A1SMN1; SMN2 | |
| SCHEMBL12746394 | 0.84 | KDM4E (0.43) | HDAC1HDAC6ALDH1A1SRCTUBB1 | |
| SCHEMBL13512685 | 0.81 | ALDH1A1 (0.50) | ALDH1A1NFE2L2TUBB1TSHRERN1 | |
| SCHEMBL19125728 | 0.78 | SRC (0.41) | CYP2A6ALDH1A1SMN1; SMN2SRCNFE2L2 | |
| SCHEMBL29950733 | 0.78 | SRC (0.41) | CYP2A6ALDH1A1SMN1; SMN2SRCNFE2L2 | |
| SCHEMBL20460600 | 0.78 | KIF11 (0.44) | CYP2A6ALDH1A1SMN1; SMN2NFE2L2KIF11 | |
| SCHEMBL48658 | 0.78 | CES2 (0.42) | CYP2A6ALDH1A1SMN1; SMN2KIF11TUBB1 | |
| SCHEMBL1811153 | 0.76 | ALDH1A1 (0.39) | CYP2A6ALDH1A1SMN1; SMN2KIF11XDH | |
| SCHEMBL6738427 | 0.76 | ALDH1A1 (0.42) | CYP2A6ALDH1A1SMN1; SMN2KIF11XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348378-A1 | SMALL MOLECULE ALBUMIN BINDERS | OREGON HEALTH & SCIENCE UNIVERSITY | 2023-11-02 | — | — | US | disclosed |
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Apollo Therapeutics Limited (GB) | 2023-08-10 | — | — | US | disclosed |
| WO-2020228685-A9 | FLUORINE-CONTAINING COMPOUND AND ANTI-CANCER MEDICAL USE THEREOF | 深圳艾欣达伟医药科技有限公司 | 2021-02-18 | — | — | WO | disclosed |
| WO-2020228685-A1 | FLUORINE-CONTAINING COMPOUND AND ANTI-CANCER MEDICAL USE THEREOF | 深圳艾欣达伟医药科技有限公司 | 2020-11-19 | — | — | WO | disclosed |
| EP-3313837-B1 | CARBOLINE ANTIPARASITICS | ZOETIS SERVICES LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20160304499-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-20 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130109734-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-8299117-B2 | GPR120 receptor agonists and uses thereof | METABOLEX INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8173704-B2 | Difluorophenol derivatives and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-08 | — | — | US | disclosed |
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20090291993-A1 | Difluorophenol Derivatives and Their Use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | HDAC1 2845/4885HDAC6 1209/4885CYP2A6 3547/4885 |
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | HDAC1 3407/4885HDAC6 3695/4885CYP2A6 2877/4885 |
| US-20230250097-A1 | BENZO[C][2,6]NAPHTHYRIDINE DERIVATIVES, COMPOSITIONS AND THERAPEUTIC USES THEREOF | CSNK1A1, CSNK1D, CSNK2A1 | HDAC1 682/4885HDAC6 1771/4885CYP2A6 1259/4885 |
| US-20090291993-A1 | Difluorophenol Derivatives and Their Use | TPMT, FABP3, DPP4 | HDAC1 1744/4885HDAC6 1012/4885CYP2A6 122/4885 |
| US-20130109734-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | HDAC1 3407/4885HDAC6 3695/4885CYP2A6 2877/4885 |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | HDAC1 3407/4885HDAC6 3695/4885CYP2A6 2877/4885 |
| US-20160304499-A1 | LXR MODULATORS | NR1H2, NR1H3, NR1H4 | HDAC1 515/4885HDAC6 1308/4885CYP2A6 190/4885 |
| US-20230348378-A1 | SMALL MOLECULE ALBUMIN BINDERS | ALB, FABP1, FABP3 | HDAC1 2839/4885HDAC6 1922/4885CYP2A6 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.